RxDoctor Payments DataLook up a doctor →

Indira Veerisetty, MD

Internal Medicine · Ridgeland, MSNPI 1720011778

Payments from drug & device makers

$24,787in general payments, 2019–2025

Across 1,257 payments — averaging $19.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$4K
  • Novo Nordisk$4K
  • AbbVie$2K
  • AstraZeneca$2K
  • Lilly USA, LLC$1K
  • Amgen$1K
  • plus $10K from 54 others

What the payments were for

  • Consulting fees$4,84020%
  • Travel & lodging$4362%
  • Food & beverage$19,31178%
  • Education$1991%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Takeda Pharmaceuticals U.S.A., Inc.61$4,463
Novo Nordisk208$4,345
AbbVie(2 entities)153$2,026
AstraZeneca84$1,696
Lilly USA, LLC126$1,482
Amgen76$1,104
Pfizer72$925
Axsome Therapeutics, Inc.34$781
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC44$629
Boehringer Ingelheim48$526
Radius Health, Inc.23$513
Teva Pharmaceuticals USA, Inc.22$484
Amarin Pharma, Inc.19$411
Johnson & Johnson29$399
Astellas Pharma US Inc16$355
Ironwood Pharmaceuticals, Inc18$351
Bayer20$347
Novartis14$336
Jazz Pharmaceuticals Inc.18$301
Esperion Therapeutics, Inc.19$293
Corcept Therapeutics13$235
Daiichi Sankyo Inc.13$233
Dexcom, Inc.5$215
Lundbeck LLC10$202
Phathom Pharmaceuticals, Inc.4$187
Sanofi-aventis U.S. LLC10$163
Merck14$161
Siemens Medical Solutions USA, Inc.3$159
Avanir Pharmaceuticals, Inc.1$125
Shield Therapeutics Inc7$113
Currax Pharmaceuticals LLC4$84
Biohaven Pharmaceutical Holding Company Ltd.5$82
Biohaven Pharmaceuticals, Inc.5$82
GSK5$70
Abbott4$67
Exact Sciences4$65
Sumitomo Pharma America, Inc.4$59
Harmony Biosciences LLC2$53
E.r. Squibb & Sons, L.L.C.4$49
Hikma Pharmaceuticals USA3$45
Arbor Pharmaceuticals, Inc.3$41
Ardelyx, Inc.2$41
Verona Pharma, Inc.2$41
Inspire Medical Systems, Inc.2$39
Eisai Inc.2$35
Medtronic2$34
Otsuka America Pharmaceutical, Inc.2$33
Sunovion Pharmaceuticals Inc.2$31
Nalpropion Pharmaceuticals LLC2$27
Sanofi Pasteur Inc.2$25
Regeneron Healthcare Solutions, Inc.1$25
Ascensia Diabetes Care US Inc.1$23
Ultragenyx Pharmaceutical Inc.1$23
Xeris Pharmaceuticals, Inc.1$23
IBSA Pharma Inc.1$21
Alvogen Inc1$20
Vifor Pharma, Inc.1$18
Averitas Pharma Inc.1$16
Supernus Pharmaceuticals, Inc.1$15
Mission Pharmacal Company1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,787 in reported general payments places this provider in the 95th percentile of 846 internal medicine providers in Mississippi.

See all internal medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$373,271
Medicare patients
606
Services billed
6,347

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide155$198,021
OzempicSemaglutide173$189,690
JardianceEmpagliflozin56$61,493
ProliaDenosumab18$30,773
EliquisApixaban32$28,777
WegovySemaglutide11$26,299
FarxigaDapagliflozin Propanediol46$25,365
TrulicityDulaglutide14$18,862
Tresiba Flextouch U-200Insulin Degludec38$16,043
RybelsusSemaglutide14$15,970
LinzessLinaclotide19$11,906
Repatha SureclickEvolocumab17$9,350
Praluent PenAlirocumab11$5,112
SynthroidLevothyroxine Sodium62$4,664
Tresiba Flextouch U-100Insulin Degludec13$3,889

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy, Rybelsus$4,345$231,959198 claims
Lilly USA, LLCMounjaro, Trulicity$1,482$216,883169 claims
Boehringer IngelheimJardiance$526$61,49356 claims
AmgenProlia$1,104$30,77318 claims
PfizerEliquis$925$28,77732 claims
AstraZenecaFarxiga$1,696$25,36546 claims
AbbVieLinzess, Synthroid$2,026$16,57081 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 846 internal medicine providers in Mississippi.

Other internal medicine in Ridgeland

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →